## Here for You. Built for Rheumatology.



## 2025 ACR RISE Registry Recommended Quality Measures List

The ACR RISE registry has identified quality measures recommended for rheumatology practices in RISE. These suggested measures represent a variety of areas important to treating patients with rheumatic diseases while also optimizing the points available for 2025 Quality Payment Programs (QPP) including traditional Merit-based Incentive Payment System (MIPS) and the new MIPS Value Pathway (MVP) reporting. This document serves solely as a resource for rheumatology practices having difficulty selecting quality measures; practices are not required to choose these as a part of their preferred measures.

See the full list of 2025 RISE Quality Measures as a reference. As a reminder, practices can only select 10 quality measures for their dashboard in RISE.

Measure Title	Measure ID#	Measure Type	Traditional MIPS and/or MVP Reporting	
*Based off the 2025 quality benchmarks, these measures below may yield the highest QPP points; these may be most optimal for practices intending to report for 2025 QPP through RISE.				
*Hepatitis B Safety Screening	ACR10	QCDR Measure	Traditional MIPS	
*Disease Activity Measurement for Patients with PsA	ACR12	QCDR Measure	вотн	
*Gout: Serum Urate Target	ACR14	QCDR Measure	вотн	
*Safe Hydroxychloroquine Dosing	ACR15	QCDR Measure	вотн	
*Rheumatoid Arthritis Patients with Low Disease Activity or Remission	ACR16	QCDR Measure	Traditional MIPS	
*Methotrexate to Biologic Adherence to Treatment Pathway for Patients with Rheumatoid Arthritis	ACR17	QCDR Measure	Traditional MIPS	
*Documentation of Current Medications in the Medical Record	eCQM130	eCQM	вотн	
*Controlling High Blood Pressure  *Preventive Care and Screening:	CQM236	CQM	Traditional MIPS	
Screening for High Blood Pressure and Follow-Up Documented	eCQM317	eCQM	Traditional MIPS	

## Here for You. Built for Rheumatology. ACR REGISTRY



In addition, these measures below are valuable to the field of rheumatology and are recommended for consideration.				
Tuberculosis Screening Prior to First Course of Biologic and/or Immune Response Modifier Therapy	CQM176	CQM	вотн	
Rheumatoid Arthritis (RA): Periodic Assessment of Disease Activity	CQM177	CQM	вотн	
Rheumatoid Arthritis (RA): Functional Status Assessment	CQM178	СОМ	вотн	
Rheumatoid Arthritis (RA): Glucocorticoid Management	CQM180	CQM	вотн	
Gains in Patient Activation Measure (PAM) Scores at 12 Months	CQM503	CQM	вотн	